ID   HTh83
AC   CVCL_0046
SY   Hth83; HTH83; HTh 83; HTh-83; hth83; U-Hth83
DR   BTO; BTO:0005148
DR   cancercelllines; CVCL_0046
DR   CCRID; 3101HUMSCSP548
DR   Cosmic; 1068624
DR   Cosmic; 1152120
DR   Cosmic; 1239973
DR   Cosmic; 2054092
DR   Wikidata; Q54896658
RX   PubMed=10918212;
RX   PubMed=17465858;
RX   PubMed=21868764;
RX   PubMed=23833040;
RX   PubMed=25365311;
RX   PubMed=30737244;
WW   https://www.proteinatlas.org/learn/cellines
CC   Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Gly456_Gly457insGly (c.1368_1369insGGA); Zygosity=Hemizygous (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000160364; Zygosity=Heterozygous (PubMed=23833040; PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro153Alafs*28 (c.455dupC) (c.455_456insC) (p.P152fs) (c.459_460insC); ClinVar=VCV000182958; Zygosity=Heterozygous (PubMed=30737244).
CC   Omics: Deep antibody staining analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
ST   Source(s): PubMed=17465858; PubMed=21868764; PubMed=25365311; PubMed=30737244
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D13S317: 11,13
ST   D16S539: 11,12
ST   D18S51: 12,14
ST   D21S11: 28,32.2
ST   D3S1358: 17
ST   D5S818: 12
ST   D7S820: 12
ST   D8S1179: 13,17
ST   FGA: 23
ST   TH01: 6,9
ST   TPOX: 8
ST   vWA: 16,19 (PubMed=17465858; PubMed=25365311; PubMed=30737244)
ST   vWA: 19 (PubMed=21868764)
DI   NCIt; C3878; Thyroid gland anaplastic carcinoma
DI   ORDO; Orphanet_142; Anaplastic thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   66Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 24
//
RX   PubMed=10918212; DOI=10.1002/1096-9896(2000)9999:9999<::AID-PATH643>3.0.CO;2-W;
RA   Dahlman T., Lammerts E., Wik M., Bergstrom D., Grimelius L.,
RA   Westermark K., Rubin K., Heldin N.-E.;
RT   "Fibrosis in undifferentiated (anaplastic) thyroid carcinomas:
RT   evidence for a dual action of tumour cells in collagen type I
RT   synthesis.";
RL   J. Pathol. 191:376-386(2000).
//
RX   PubMed=17465858; DOI=10.1089/thy.2006.0246;
RA   Lee J.-J., Foukakis T., Hashemi J., Grimelius L., Heldin N.-E.,
RA   Wallin G., Rudduck C., Lui W.-O., Hoog A., Larsson C.;
RT   "Molecular cytogenetic profiles of novel and established human
RT   anaplastic thyroid carcinoma models.";
RL   Thyroid 17:289-301(2007).
//
RX   PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690;
RA   Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C.,
RA   Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G.,
RA   Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.;
RT   "Assembly and initial characterization of a panel of 85 genomically
RT   validated cell lines from diverse head and neck tumor sites.";
RL   Clin. Cancer Res. 17:7248-7264(2011).
//
RX   PubMed=23833040; DOI=10.1210/jc.2013-2383;
RA   Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M.,
RA   Ibrahimpasic T., Ghossein R.A., Fagin J.A.;
RT   "Frequent somatic TERT promoter mutations in thyroid cancer: higher
RT   prevalence in advanced forms of the disease.";
RL   J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013).
//
RX   PubMed=25365311; DOI=10.1210/jc.2014-2359;
RA   Garg M., Okamoto R., Nagata Y., Kanojia D., Venkatesan S., Anand M.T.,
RA   Braunstein G.D., Said J.W., Doan N.B., Ho Q., Akagi T., Gery S.,
RA   Liu L.-Z., Tan K.T., Chang W.J., Yang H., Ogawa S., Koeffler H.P.;
RT   "Establishment and characterization of novel human primary and
RT   metastatic anaplastic thyroid cancer cell lines and their genomic
RT   evolution over a year as a primagraft.";
RL   J. Clin. Endocrinol. Metab. 100:725-735(2015).
//
RX   PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953;
RA   Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C.,
RA   Copland J.A. III, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N.,
RA   Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R.,
RA   Fagin J.A., Schweppe R.E.;
RT   "Comprehensive genetic characterization of human thyroid cancer cell
RT   lines: a validated panel for preclinical studies.";
RL   Clin. Cancer Res. 25:3141-3151(2019).
//